Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis (Journal of Neurology (2006) 253, (SUPPL. 5) (50-58) DOI: 10.1007/s00415-006-5007-x);Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis

Journal of Neurology

Volumn 253, Issue SUPPL. 5, 2006, Pages 308-

  Dudesek, Ales ^a   Zettl, Uwe K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Chronic progressive MS; Clinically isolated syndrome; Intravenous immunoglobulin; Relapsing remitting MS; Remyelination

Indexed keywords

BETA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN;

BREAST FEEDING; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 33748964286     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-008-0881-z     Document Type: Erratum

References (51)

1. Achiron A, Pras E, Gilad R, Ziv I, Mandel M, Gordon CR, Noy S, Sarova-Pinhas I, Melamed E (1992) Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting Multiple Sclerosis. Arch Neurol 49:1233-1236
2. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398-402
3. Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, Achiron R (2004) Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251:1133-1137
4. Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61:1515-1520
5. Bieber A, Asakura K, Warrington A, Kaveri SV, Rodriguez M (2000) Antibody-mediated remyelination: relevance to multiple sclerosis. Mult Scler 6(Suppl 2):S1-S5
6. Bjartmar C, Wujek JR, Trapp BD (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206:165-171
7. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR. Early Treatment of Multiple Sclerosis Study Group (2001) Effect on early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576-1582
8. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290-297
9. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770-782
10. Cook SD, Troiano R, Rohowsky-Kochan C, Jotkowitz A, Bielory L, Mehta PD, Oleske J, Bansil S, Dowling PC (1992) Intravenous gamma globulin in progressive MS. Acta Neurol Scand 86:171-175
11. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC (1994) A plasma exchange versus immune globuline infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838-845
12. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349:589-593
13. Haas J, Maas-Enriquez M, Hartung HP (2005) Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years. Mult Scler 11:562-567
14. Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, Pozilli C, O'Connor P (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149-1156
15. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group. N Engl J Med 343:898-904
16. rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
17. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268-1276
18. Kappos L, Polman C, Freedman MS, Edan GC, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Sandbrink R on behalf of the BENEFIT Study Group (2005) Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): clinical results. Mult Scler (Suppl 1):10
19. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131-156
20. Koçer B, Yildirim-Gurel S, Tali ET, Irkec C, Isik S (2004) The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G. Neuroradiology 46:287-290
21. Lewanska M, Siger-Zajdel M, Selmaj K (2002) No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 9:565-572
22. MS-Therapie Konsensus Gruppe (1999) Immunomodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 70:371-386
23. MS-Therapie Konsensus Gruppe (2000) Immunomodulatorische Stufentherapie der multiplen Sklerose. I. Ergänzung. Nervenarzt 72:150-157
24. MS-Therapie Konsensus Gruppe (2002) Immunmodulatorische Stupentherapie der multiplen Sklerose. Neue Aspekte und praktische Umsetzung. Nervenarzt 73:556-563
25. Multiple Sclerosis Therapy Consensus Group (2004) Escalating immunotherapy of multiple sclerosis. J Neurol 251:1329-1339
26. Murray PD, McGavern DB, Sathornsumetee S, Rodriguez M (2001) Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis. Brain 124:1403-1416
27. Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, Sneve D, Cross SA, Leavitt JA, Auger RG, Weinshenker BG, Dodick DW, Wingerchuk DM, Rodriguez M (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514-1522
28. Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, Windebank AJ, Whisnant JP, Stolp-Smith KA, Harper CM Jr, Low PA, Romme LJ, Johnson M, An KN, Rodriguez M (2000) IV immunoglobulin does not reverse established weakness in MS. Neurology 55:1135-1143
29. a) Pöhlau D, Federlein J, Postert T, Sailer M, Bethke F, Kappos L, Haas J, Przuntek H (1997) Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis - outline of a double-blind randomized, placebo-controlled trial. Mult Scler 3:149-152
30. b) Pöhlau D, Przuntek H, Späth P, Andresen I and the IVIG Study Group (2005) Intravenous immunoglobulin treatment for patients with primary or secondary progressive multiple sclerosis. Mult Scler (Suppl 1):163
31. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
32. Prineas JW, Kwon EE, Cho E, Sharer LR, Barnett MH, Oleszak EL, Hoffman B, Morgan BP (2001) Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50:646-657
33. Rodriguez M, Lennon VA (1990) Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 27:12-17
34. Rodriguez M, Miller DJ, Lennon VA (1996) Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 46:538-545
35. Roed HG, Langkilde A, Sellebjerg FT, Lauritzen M, Bang P, Morup A, Frederiksen JL (2005) A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64:804-810
36. Rothfelder U, Neu I, Pelka R (1982) Therapy of multiple sclerosis with immunoglobulin G MMW Munch Med Wochenschr 124:74-78
37. Schuller E, Govaerts A (1983) First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 22:205-212
38. Simone IL, Carrara D, Tortorella C, Ceccarelli A, Livrea P (2000) Early onset multiple sclerosis. Neurol Sci 21(4 Suppl 2):S861-S863
39. Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen V, Lee ML (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273-1281
40. Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557-563
41. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M; TARIMS Study Group (2004) IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63:2028-2033
42. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S (2000) Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89-92
43. Stangel M, Gold R (2004) Use of IV immunoglobulins in neurology. Evidence-based consensus. Nervenarzt 75:801-815
44. Stangel M, Hartung HP (2002) Despair of repair. J Neurol Neurosurg Psychiatry 72:1-4
45. Teksam M, Tali T, Kocer B, Isik S (2000) Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 42:885-889
46. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
47. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285
48. van der Meche FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123-1129
49. van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF (1991) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neur 48:217-220
50. Vermeulen M, Van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36-39
51. Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW (2004) A randomized, double-blind, placebo-controlled pilot study of i. v. immune globulins in combination i.v methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 10:89-91